Five-year follow-up of patients with difficult-to-treat rheumatoid arthritis

Rheumatoid Arthritis

Prevalence and Characteristics of Adults with Difficult-to-Treat Rheumatoid Arthritis in a Large Patient Registry

Rheumatology (Oxford)

Paudel ML, Li R, Naik C, Shadick N, Weinblatt ME, Solomon DH

doi: 10.1093/rheumatology/keae318

Rheumatoid Arthritis

Which advanced treatment should be used following the failure of a first-line anti-TNF in patients with rheumatoid arthritis? 15 years of evidence from the Quebec registry RHUMADATA

Rheumatology (Oxford)

Choquette D, Haraoui B, Movahedi M, Bessette L, Sauvageau LC, Ferdinand I, Joly-Chevrier M, Masetto A, Massicotte F, Nadon V, Pelletier JP, Raynauld JP, Sauvageau D, Villeneuve É, Coupal L

doi: 10.1093/rheumatology/keae283

Rheumatoid Arthritis

Is a 1-year course of methotrexate in patients with arthralgia at-risk for rheumatoid arthritis cost-effective? A cost-effectiveness analysis of the randomised, placebo-controlled TREAT EARLIER trial

Ann Rheum Dis

van Mulligen E, Bour SS, Goossens LMA, de Jong PHP, Rutten-van Mölken M, van der Helm-van Mil A

doi: 10.1136/ard-2024-226286

Rheumatoid Arthritis

Predictors of arthritis development in individuals at risk of rheumatoid arthritis: a 5-year follow-up study from a large cohort

Ann Rheum Dis

Frazzei G, Landewé RBM, Wagenaar C, van de Stadt LA, van Schaardenburg D, Tas SW, van Vollenhoven RF

doi: 10.1016/j.ard.2025.01.042

Rheumatoid Arthritis

Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports

Semin Arthritis Rheum

Goldman A, Galper BL, Druyan A, Grossman C, Sharif K, Shechtman L, Moshkovits Y, Lahat A, Ben-Zvi I

doi: 10.1016/j.semarthrit.2024.152461

EULAR 2024

Psoriatic Arthritis

PRO-SPIRIT: Real-world comparison of five therapies for treating patients with psoriatic arthritis

Psoriatic Arthritis

Interstitial lung disease in rheumatoid or psoriatic arthritis patients initiating biologics, and controls - data from five Nordic registries

J Rheumatol

Provan SA, Ljung L, Kristianslund EK, Michelsen B, Uhlig T, Jonmundsson T, Sexton J, Gudbjornsson B, Di Giuseppe D, Hetland ML, Reynisdottir GB, Glintborg B, Relas H, Aaltonen K, Kvien TK, Askling J

doi: 10.3899/jrheum.2024-0252

Rheumatoid Arthritis

Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years

Ann Rheum Dis

Burmester GR, Gottenberg JE, Caporali R, Winthrop KL, Tanaka Y, Ekoka Omoruyi EV, Rajendran V, Van Hoek P, Van Beneden K, Takeuchi T, Westhovens R, Aletaha D

doi: 10.1136/ard-2024-225759

Rheumatoid Arthritis

Association of patient- and hospital-level predictors with patterns of initial treatment in patients with Rheumatoid Arthritis: findings from a national cohort study

Rheumatology (Oxford)

Yang Z, Alveyn E, Russell M, Bechman K, Coalwood C, Price E, Abhishek A, Norton S, Galloway J

doi: 10.1093/rheumatology/keae717

Related content

Prevalence and Characteristics of Adults with Difficult-to-Treat Rheumatoid Arthritis in a Large Patient Registry

Which advanced treatment should be used following the failure of a first-line anti-TNF in patients with rheumatoid arthritis? 15 years of evidence from the Quebec registry RHUMADATA

Is a 1-year course of methotrexate in patients with arthralgia at-risk for rheumatoid arthritis cost-effective? A cost-effectiveness analysis of the randomised, placebo-controlled TREAT EARLIER trial

Predictors of arthritis development in individuals at risk of rheumatoid arthritis: a 5-year follow-up study from a large cohort

Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports

PRO-SPIRIT: Real-world comparison of five therapies for treating patients with psoriatic arthritis

Interstitial lung disease in rheumatoid or psoriatic arthritis patients initiating biologics, and controls - data from five Nordic registries

Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years

Association of patient- and hospital-level predictors with patterns of initial treatment in patients with Rheumatoid Arthritis: findings from a national cohort study